2. Search Result
Search Result
Results for "

pyrimidine base

" in MedChemExpress (MCE) Product Catalog:

17

Inhibitors & Agonists

2

Natural
Products

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-I0960
    Uracil
    4 Publications Verification

    		 Endogenous Metabolite Drug Derivative Infection Cancer
    Uracil is a pyrimidine derivative and one of the four nucleobases in the nucleic acid of RNA. Uracil is a frequently occurring DNA base damage that results from the spontaneous or chemically induced deamination of cytosine and is mutagenic at the level of replication. Uracil could potentially alter transcriptional fidelity, resulting in production of mutant proteins .
    Uracil
  • HY-171932
    CaMKIIδ-IN-1

    		CaMK Cardiovascular Disease
    CaMKIIδ-IN-1 (Compound 15e) is a pyrimidine-based inhibitor of CaMKIIδ with an IC50 of 12 nM .
    CaMKIIδ-IN-1
  • HY-W587907
    5-Formylcytidine

    		Drug Derivative Others
    5-Formylcytosine is a pyrimidine nitrogen base derived from cytosine .
    5-Formylcytidine
  • HY-18622
    PP58

    		Src FGFR PDGFR Cancer
    PP58 is a pyrido[2,3-d]pyrimidine-based compound that inhibits PDGFR, FGFR and Src family activities with nanomolar IC50 values.
    PP58
  • HY-128788
    ddhCTP

    		DNA/RNA Synthesis SARS-CoV Endogenous Metabolite Flavivirus Lactate Dehydrogenase Infection
    ddhCTP is an endogenously produced pyrimidine base analog with a Kd of 17.0 nM for LLDH and an IC50 of 55.8 μM for GAPDH. By inhibiting key metabolic enzymes such as GAPDH, ddhCTP reduces glycolytic flux and shifts metabolic flow toward the pentose phosphate pathway, thereby regulating the redox balance of cells. As a competitive CTP analog, ddhCTP terminates RNA synthesis by flavivirus RdRps and SARS-CoV-2 RdRp, and inhibits Zika virus replication in vivo. ddhCTP can be used in studies related to viral infections, COVID-19 and Zika virus infections.
    ddhCTP
  • HY-20176
    2,4-Dichlorothieno[3,2-d]pyrimidine

    		Drug Intermediate Adenosine Receptor PI3K Infection
    2,4-Dichlorothieno[3,2-d]pyrimidine is a thienopyrimidine scaffold and a key synthetic precursor, which is widely used for constructing 4-arylthieno[3,2-d]pyrimidine compounds. 2,4-Dichlorothieno[3,2-d]pyrimidine serves for the development of 4-arylthieno[3,2-d]pyrimidine-based human adenosine A2a receptor antagonists, as well as thienopyrimidine-based PI3K-α inhibitors. In addition, 2,4-Dichlorothieno[3,2-d]pyrimidine has potential application value in studies related to whipworm disease .
    2,4-Dichlorothieno[3,2-d]pyrimidine
  • HY-162469
    6K465

    		Aurora Kinase c-Myc Cancer
    6K465 is a pyrimidine-based Aurora A (AURKA) inhibitor. 6K465 can reduce the levels of c-MYC and N-MYC oncoproteins, demonstrating anticancer activity .
    6K465
  • HY-171932A
    CaMKIIδ-IN-1 hydrochloride

    		CaMK Cardiovascular Disease
    CaMKIIδ-IN-1 (Compound 15e) hydrochloride is a pyrimidine-based inhibitor of CaMKIIδ with an IC50 of 12 nM .
    CaMKIIδ-IN-1 hydrochloride
  • HY-134529
    D-Ribofuranose1-dihydrogenphosphate

    Ribose 1-phosphate

    		 Endogenous Metabolite Others
    D-Ribofuranose 1-dihydrogenphosphate (Ribose 1-phosphate) dicyclohexanamine is a pentose phosphate and serves as a key intermediate metabolite in the salvage synthesis pathway of purine and pyrimidine nucleotides. In nucleotide salvage synthesis, D-Ribofuranose 1-dihydrogenphosphate dicyclohexanamine directly "transfers" the ribosyl group from purine nucleosides to pyrimidine bases, acting as a hub molecule linking nucleoside/base metabolism with pentose phosphate metabolism .
    D-Ribofuranose1-dihydrogenphosphate
  • HY-137602
    P1,P2-Diuridine-5’-diphosphate

    Up2U

    		 P2Y Receptor Others
    P1,P2-Diuridine-5’-diphosphate (Up2U) is a symmetrical dinucleoside polyphosphate containing two pyrimidine base moieties. P1,P2-Diuridine-5’-diphosphate is also an activator of purinergic P2Y receptor .
    P1,P2-Diuridine-5’-diphosphate
  • HY-161071
    Antioxidant/anticancer agent 1

    		Fungal Infection Cancer
    Antioxidant/anticancer agent 1 (compound 5) is a pyrimidine-derivatized Schiff base based on pyrimidine hydroxy-1-naphthaldehyde and has antibacterial, antioxidant, antifungal, and anticancer properties. Antioxidant/anticancer agent 1 .
    Antioxidant/anticancer agent 1
  • HY-139920A
    Oritinib mesylate

    SH-1028 mesylate

    		 EGFR Cancer
    Oritinib (SH-1028) mesylate is a selective, orally active, and pyrimidine-based irreversible inhibitor of EGFR with an IC50 of 18 nM. Oritinib (SH-1028) mesylate exhibits potent activity against EGFR sensitive and resistant (T790 M) mutations. Oritinib (SH-1028) mesylate significantly inhibits proliferation of tumor cells with EGFR sensitive and resistant mutation .
    Oritinib mesylate
  • HY-134369
    Ap4C tetrasodium

    		P2Y Receptor Others Inflammation/Immunology
    Ap4C tetrasodium is a dinucleoside polyphosphate containing purine and pyrimidine base moieties. Ap4C tetrasodium acts as a signaling molecule by binding to specific P2Y receptors, activating P2Y2 and P2Y4 receptors in platelets, leading to platelet aggregation and other cellular responses. Ap4C tetrasodium can be used for research in inflammation and blood coagulation .
    Ap4C tetrasodium
  • HY-W014109
    (E)-5-(2-Bromovinyl)pyrimidine-2,4(1H,3H)-dione

    (E)-5-(2-Bromovinyl)uracil; BVU

    		 DNA/RNA Synthesis Infection
    (E)-5-(2-Bromovinyl)uracil (BVU) is a pyrimidine base and an inactive metabolite of the antiviral agents sorivudine and (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) that may be regenerated to BVDU in vivo. BVU irreversibly inactivates dihydropyrimidine dehydrogenase (DPD) in an NADPH-dependent manner. It enhances the efficacy of the chemotherapeutic agent and DPD substrate 5-fluorouracil (HY-90006) in a P388 murine leukemia model when administered at a dose of 200 μmol/kg, increasing survival time.
    (E)-5-(2-Bromovinyl)pyrimidine-2,4(1H,3H)-dione
  • HY-183131
    CaMKII-IN-4

    		CaMK Others
    CaMKII-IN-4 is a pyrimidine-based ATP-competitive CaMKIIδ inhibitor with an enzymatic IC50 of >20 μM .
    CaMKII-IN-4
  • HY-W998269
    6-(2,6-Dioxopiperidin-3-yl)-2-(piperazin-1-yl)-5H-pyrrolo[3,4-d]pyrimidine-5,7(6H)-dione hydrochloride

    		E3 Ligase Ligand-Linker Conjugates Cancer
    6-(2,6-Dioxopiperidin-3-yl)-2-(piperazin-1-yl)-5H-pyrrolo[3,4-d]pyrimidine-5,7(6H)-dione hydrochloride is an E3 ligase ligand-linker conjugate containing a CRBN-based ligand and linker, which can be used to synthesize PROTAC.
    6-(2,6-Dioxopiperidin-3-yl)-2-(piperazin-1-yl)-5H-pyrrolo[3,4-d]pyrimidine-5,7(6H)-dione hydrochloride
  • HY-128788A
    ddhCTP trisodium solution (100 mM)

    		DNA/RNA Synthesis SARS-CoV Endogenous Metabolite Flavivirus Lactate Dehydrogenase Infection
    ddhCTP trisodium solution (100 mM) is an endogenously produced pyrimidine base analog with a Kd of 17.0 nM for LLDH and an IC50 of 55.8 μM for GAPDH. By inhibiting key metabolic enzymes such as GAPDH, ddhCTP trisodium reduces glycolytic flux and shifts metabolic flow toward the pentose phosphate pathway, thereby regulating the redox balance of cells. As a competitive CTP analog, ddhCTP trisodium terminates RNA synthesis by flavivirus RdRps and SARS-CoV-2 RdRp, and inhibits Zika virus replication in vivo. ddhCTP trisodium can be used in studies related to viral infections, COVID-19 and Zika virus infections .
    ddhCTP trisodium solution (100 mM)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: